IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A compound of formula (I), ~~their analogs,~~ their stereoisomers, tautomeric forms, or their pharmaceutically acceptable salts~~, their pharmaceutically acceptable solvates, and pharmaceutical compositions containing them~~,



(I)

~~Where~~ Ar represents an optionally substituted phenyl ring[[,]] or heteroaromatic group comprising five or six membered ~~hetero aromatic ring which may be substituted or unsubstituted~~ heterocyclic radicals containing one or more hetero atoms selected from O, N or S, attached to an aryl group, wherein each of the groups may be substituted;

R_1 & R_2 may be same or different and represent hydrogen, halogen, ~~substituted or unsubstituted groups selected from~~ (C_1-C_6) alkyl, aralkyl, alkoxy, thio, amino, aminoalkyl, nitro, cyano, formyl, thioalkoxy, (C_3-C_7) cycloalkyl, haloalkyl, or haloalkoxy~~, groups~~;

Y represents the groups G_1, G_2 or G_3:



G_1 G_2 G_3

where R_3 & R_4 may be same or different and represent H, C_1-C_6 ~~substituted or unsubstituted~~ linear or branched alkyl group, halogen, hydroxy, cyano, haloalkyl, haloalkoxy, perhaloalkoxy, thio, substituted or unsubstituted groups selected from (C_3-C_7) cycloalkyl, (C_1-$C_{6[12]}$) alkoxy, cyclo (C_3-C_7) alkoxy, aryl groups containing one, two

or three rings wherein such rings may be attached together in a pendant manner or may be fused, aryloxy, aralkyl, ar(C_1-$C_{6[[12]]}$) alkoxy, acyl, acyloxy, carboxylic acid and its derivatives ~~such as esters and amides~~ selected from alkyl or aryl esters and alkyl or aryl amides, hydroxyalkyl, aminoalkyl, mono-substituted or di-substituted aminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, (C_1-$C_{6[[12]]}$) alkylthio, thio (C_1-$C_{6[[12]]}$) alkyl & arylthio; X represents O, S or NR^5 where R^5 represents H or (un)substituted alkyl or aryl groups;

A represents a (un)substituted, saturated or unsaturated or partially saturated single or fused ring moiety, optionally containing one or more heteroatoms selected from N, S, O; Z represents H, ~~C_1-C_6 substituted or unsubstituted alkyl group,~~ cyano, haloalkyl, ~~haloalkoxy, perhaloalkoxy,~~ substituted or unsubstituted groups selected from (C_1-C_6) alkyl, (C_3-C_7) cycloalkyl, ~~bicycloalkyl,~~ (C_1-$C_{6[[12]]}$) alkoxy, cyclo ([[C]] C_3-C_7) alkoxy, aryl, aryloxy, aralkyl, ar([[C]] C_1-C_{12}) alkoxy, heterocyclyl group selected from 4-12 membered saturated, partially saturated and unsaturated ring-shaped radicals, the heteroatoms selected from nitrogen, sulfur or oxygen; heteroaryl, ~~heterocyclyl(C_1-C_{12})alkyl, heteroar(C_1-C_{12})alkyl, heteroaryloxy, heteroar(C_1-C_{12})alkoxy, heterocycloxy, heterocyclylalkyloxy,~~ acyl, ~~acyloxy, acylamino,~~ carboxylic acid and its derivatives selected from alkyl or aryl esters and alkyl or aryl amides, ~~such as esters and amides, hydroxyalkyl, aminoalkyl, mono-substituted or di-substituted aminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl,~~ (C_1-$C_{6[[12]]}$) alkylthio, thio (C_1-$C_{6[[12]]}$) alkyl, ~~arylthio,~~ SOR_6 and SO_2R_6, where R_6 represents amino, optionally substituted groups selected from alkyl, aryl, heteroaryl, heterocyclyl groups; the dotted line '------' represents either a bond or a no bond[[.]];

W represents OH, N_3, NH_2, NCS, OSO_2CH_3 or a moiety of general formula



Wherein R_7 may be H, substituted or unsubstituted groups selected from amino, alkylamino, dialkylamino, aralkylamino, (C_1-C_6) alkoxy, (C_1-C_{12}) alkyl, aralkyl, (C_3-$C_{7[[12]]}$)

cycloalkyl, [[C]] {C_1-C_6} thioalkyl, {C_1-C_6} haloalkyl, thioalkoxy, and X is selected from O, S, --NR_5 where R_5 represents H, or substituted or unsubstituted alkyl group or aryl groups.

2. (original) A compound as defined in claim 1 wherein substituents on groups A & Z are selected from cyano, nitro, halo, perhaloalkyl, carboxyl, hydrazino, azido, formyl, amino, thio, hydroxy, sulfenyl, or substituted or unsubstituted groups selected from alkyl which may be linear or branched; cycloalkyl, alkenyl, cycloalkenyl, alkynyl, hydrazinoalkyl, alkylhydrazido, hydroxylamino, acyl, acyloxy, acylamino, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylaminoalkyl, arylamino, alkylamino, aralkylamino, aralkoxy, haloaralkyl, aralkenyl, aryl, aralkyl, aryloxy, alkoxy, alkylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylcarbonylalkyl, alkoxycarbonylalkyl, 1-alkoxycarbonyloxy-alkyl, 1-cycloalkyloxycarbonyloxy-alkyl, carboxamidoalkyl, cyanoamidino, cyanoalkyl, aminocarbonylalkyl, N-aminocarbonylalkyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, carboxyalkylaminocarboxy, N-alkylamino, N,N-dialkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-aralkyl-N-alkylaminoalkyl, N-alkyl-N-arylaminoalkyl, N,N-dialkylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, N-alkyl-N-hydroxyaminocarbonyl, N-alkyl-N-hydroxyaminocarbonylalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, arylthio, aralkylthio, alkoxycarbonyl, aminocarbonyl, alkoxycarbonylamino, cycloalkyl, bicycloalkyl, cycloalkoxy, bicycloalkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, heterocycloalkoxycarbonyl, heteroaryloxycarbonyl, heteroaralkoxycarbonyl, RSO_2NH-- and RSO_2O-- groups wherein R represents alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl groups.

3. (original) A compound as claimed in claim 1 where R^1 is hydrogen and R^2 is halo.

4. (original) A compound as claimed in claim 1 where Ar represents a phenyl ring.

5. (currently amended) A composition comprising a compound of formula (I)[[,]] or a therapeutically acceptable salt ~~or prodrug~~ thereof and a therapeutically acceptable excipient.

6. (currently amended) A pharmaceutical composition according to claim 5 [[6;]] in the form of a tablet, capsule, powder, granules, syrup, solution or suspension.

7. (currently amended) A method for treating bacterial infections caused by Gram positive bacteria or[[,]] psoriasis[[,]] ~~arthritis~~ in mammals comprising administering a therapeutically acceptable amount of compound of formula (I)[[,]] or a therapeutically acceptable salt ~~or prodrug~~ thereof.

8. (currently amended) The method as claimed in claim 7 wherein the compound or therapeutically acceptable salt thereof is administered orally, nasally, parenterally, topically, transdermally, or rectally.

9. (withdrawn/currently amended) A method for treating toxicity due to chemotherapy in a patient comprising administering a therapeutically acceptable amount of a compound of formula (I)[[,]] or a therapeutically acceptable salt ~~or prodrug~~ thereof.

10. (withdrawn/currently amended) The method as claimed in claim 9 wherein the compound or therapeutically acceptable salt thereof is administered orally, nasally, parenterally, topically, transdermally, or rectally.

11. (currently amended) A compound according to claim 1 which is selected from the group consisting of:
(S)-N-[3-(3-Fluoro-4-{4-[3-(4-hydroxyphenyl)-acryloyl]-piperazin-1-yl]-ph- enyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-hydroxyphenyl)-acryloyl]-piperazin-1-yl]-ph- enyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(4-hydroxyphenyl)-acryloyl]-piperazin-1-yl]-ph- enyl)-2-oxo-oxazolidin-5-yl methyl]thiourea;
(S)-N-[3-(3-Fluoro-4-{4-[3-(3-hydroxyphenyl)-acryloyl]-piperazin-1-yl]-ph- enyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(3-hydroxyphenyl)-acryloyl]-piperazin-1-yl]-ph- enyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-{4-(4-(3-Benzo[1,3]-dioxol-5-yl-acryloyl)-piperazin-1-yl}-3-fluo- rophenyl]-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-{4-(4-(3-Benzo[1,3]-dioxol-5-yl-acryloyl)-piperazin-1-yl}-3-fluo- rophenyl]-2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-{4-(4-(3-Benzo[1,3]-dioxol-5-yl-acryloyl)-piperazin-1-yl}-3-fluo- rophenyl]-2-oxo-oxazolidin-5-yl methyl]thiourea;
(S)-N-[3-(3-Fluoro-4-{4-[3-(thiophen-3-yl)-acryloyl]-piperazinyl]-phenyl)- -2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(thiophen-2-yl)-acryloyl]-piperazinyl]-phenyl)- -2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(thiophen-2-yl)-acryloyl]-piperazinyl]-phenyl)- -2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(thiophen-2-yl)-acryloyl]-piperazinyl]-phenyl)- -2-oxo-oxazolidin-5-yl methyl]thiourea;
(S)-N-[3-(3-Fluoro-4-{4-[3-(thiophen-2-yl)-acryloyl]-piperazinyl]-phenyl)- -2-oxo-oxazolidin-5-yl methyl]thiocarbamate;
(S)-N-[3-(3-Fluoro-4-{4-[3-(1H-indol-3-yl)-acryloyl]-piperazin-1-yl]-phen- yl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(1H-indol-3-yl)-acryloyl]-piperazin-1-yl]-phen- yl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(1H-indol-3-yl)-acryloyl]-piperazin-1-yl]-phen- yl)-2-oxo-oxazolidin-5-yl methyl]thiourea;

(S)-N-[3-(3-Fluoro-4-{4-[3-(furan-2-yl)-acryloyl]-piperazin-1-yl]-phenyl)- -2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(furan-2-yl)-acryloyl]-piperazin-1-yl]-phenyl)- -2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(furan-2-yl)-acryloyl]-piperazin-1-yl]-phenyl)- -2-oxo-oxazolidin-5-yl methyl]thiourea;
(S)-N-[3-(3-Fluoro-4-{4-[3-(pyridin-3-yl)-acryloyl]-piperazin-1-yl]-pheny- l)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(pyridin-3-yl)-acryloyl]-piperazin-1-yl]-pheny- l)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(pyridin-4-yl)-acryloyl]-piperazin-1-yl]-pheny- l)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(pyridin-4-yl)-acryloyl]-piperazin-1-yl]-pheny- l)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(pyridin-4-yl)-acryloyl]-piperazin-1-yl]-pheny- l)-2-oxo-oxazolidin-5-yl methyl]thiourea;
(S)-N-[3-(3-Fluoro-4-{4-[3-phenyl-propanoyl]-piperazin-1-yl]-phenyl)-2-ox- o-oxazolidin-1 5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-phenyl-propanoyl]-piperazin-1-yl]-phenyl)-2-ox- o-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(4-fluorophenyl)-acryloyl]-piperazin-1-yl]-phe- nyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(4-fluorophenyl)-acryloyl]-piperazin-1-yl]-phe- nyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-(3-Fluoro-4-{4-[3-(4-fluorophenyl)-acryloyl]-piperazin-1-yl]-phe- nyl)-2-oxo-oxazolidin-5-yl methyl]thiourea;
(S)-N-[3-(3-Fluoro-4-{4-[3-(4-fluorophenyl)-acryloyl]-piperazin-1-yl]-phe- nyl)-2-oxo-oxazolidin-5-yl methyl]thiocarbamate;
(S)-N-[3-(3-Fluoro-4-{4-[3-phenyl acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-phenyl acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-phenyl acryloyl]-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]thiourea;

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-methoxyphenyl)acryloyl)-piperazin-1-yl]-phe- nyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-methoxyphenyl)acryloyl)-piperazin-1-yl]-phe- nyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-methoxyphenyl)acryloyl)-piperazin-1-yl]-phe- nyl)-2-oxo-oxazolidin-5-yl methyl]thiourea;

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-acetoxyphenyl)acryloyl)-piperazin-1-yl]-phe- nyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-acetoxyphenyl)acryloyl)-piperazin-1-yl]-phe- nyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-acetoxyphenyl)acryloyl)-piperazin-1-yl]-phe- nyl)-2-oxo-oxazolidin-5-yl methyl]thiourea;

(S)-N-[3-(3-Fluoro-4-{4-[3-furan-3-yl-acryloyl)-piperazin-1-yl]-phenyl)-2- -oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-(3,4-difluorophenyl)-acryloyl)-piperazin-1-yl]- -phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-(3,4-difluorophenyl)-acryloyl)-piperazin-1-yl]- -phenyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;

(S)-N-[3-(3-Fluoro-4-{4-[3-(3,4-difluorophenyl)-acryloyl)-piperazin-1-yl]- -phenyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;

Methanesulfonic acid 4-[3-(4-{4-[5-(acetyl aminomethyl)-2-oxo-oxazolidin-3-yl]-2-fluorophenyl}piperazin-1-yl]-3-oxo-- propenyl]-phenyl ester,

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-methylsulfanyl-phenyl)-acryloyl)-piperazin-- 1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(4-{4-[3-(3,4-dihydroxyphenyl)-acryloyl)-piperazin-1-yl]-3-fluor- ophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(4-{4-[3-biphenyl-4-yl-acryloyl)-piperazin-1-yl]-3-fluorophenyl)- -2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(4-{4-but-2-enoyl-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolid- in-5-yl methyl]acetamide;

(S)-N-[3-(4-{4-acryloyl-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-- 5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-{4-[2-methylacryloyl-piperazin-1-yl]-phenyl)-2-oxo-o- xazolidin-5-yl methyl]acetamide;

(S)-N-[3-(-4-{4-[3-(4-benzyloxy-phenyl)-acryloyl)-piperazin-1-yl]-3-fluor- ophenyl)-2-oxo-oxazolidin-5-yl methyl]thiourea;

(S)-N-[3-(4-{4-[3-(4-nitrophenyl)-acryloyl)-piperazin-1-yl]-3-fluoropheny- l)-2-oxo-oxazolidin-5-yl methyl]acetamide;

Carbonic acid-1-{4-[3-(4-{4-[5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluor-ophenyl}-piperazin-1-yl)-3-oxo-propenyl]-phenoxy}-ethyl ether cyclohexyl ester;

(S)-N-[3-(4-{4-[3-(4-aminophenyl)-acryloyl)-piperazin-1-yl]-3-fluo- rophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(4-{4-[3-(3,4-diacetoxy-phenyl)-acryloyl)-piperazin-1-yl]-3-fluo- rophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(4-{4-[3-benzo[1,3]-dioxol-5-yl acryloyl)-piperazin-1-yl]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]thiocarbamate;

(S)-N-[3-(3-Fluoro-4-[4-(4-oxo-4-phenyl-but-2-enoyl)-piperazin-1-yl]-phen- yl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-[4-(4-(4-methoxyphenyl)-4-oxo-but-2-enoyl)-piperazin- -1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-[4-(4-(4-methoxyphenyl)-4-oxo-but-2-enoyl)-piperazin- -1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;

(S)-N-[3-{4-[4-(4-(4-acetylaminophenyl)-4-oxo-but-2-enoyl)-piperazin-1-yl-]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-[4-(4-(4-acetylaminophenyl)-acryloyl)-piperazin-1-yl-]-3-fluorophenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-[4-(3-cyclohexyl)-acryloyl-piperazin-1-yl]-3-fluorop- henyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
Acetic acid-2-(4-{4-[5-(acetylaminomethyl)-2-oxo-oxazolidin-3-yl]-2-fluorophenyl-][-piperazinyl-1-carbonyl-7-amino-3-oxo-5-thia-1-aza-bicyclo-[4.2.0]-oct-2- -en-3-yl-methyl ester; 2,2-Dimethyl-propanoic acid-4-(3-(4-{4-[5-(acetylaminomethyl)-2-oxo-oxazolidin-3-yl]-2-fluorophe- nyl}piperazinyl-1-yl)-3-oxo-propenyl]phenyl ester;
Carbonic acid-1-{4-[3-(4-{4-[5-(acetylaminomethyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl][-piperazinyl-1-yl)-3-oxo-propenyl]phenyl ester;
(S)-N-[3-(3-Fluoro-4-[4-(3-(5-nitrofuran-2-yl)-acryloyl-piperazin-1-yl]-3- -phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-[4-(6-methoxy-1-oxo-1,2,3,4 tetrahydronaphthalen-2-yl methyl)-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-[4-(1-oxo-1,2,3,4 tetrahydronaphthalen-2-yl methyl)-piperazin-1-yl]-3-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-[4-(5-methoxy-1-oxo-indan-2-yl-methyl)-piperazin-1-y- l]-3-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-[4-(2-oxo-cyclohexylmethyl)-piperazin-1-yl]-3-phenyl-)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-[4-(6-methoxy-1-oxo-1,2,3,4 tetrahydronaphthalen-2-yl methyl)-piperazin-1-yl]-3-phenyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-(3-Fluoro-4-[4-(5-methoxy-1-oxo-indan-2-yl-methyl)-piperazin-1-y- l]-3-phenyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;
(S)-N-[3-(3-Fluoro-4-[4-(1-hydroxyimino-6-methoxy-1,2,3,4 tetrahydronaphthalen-1-yl methyl)-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide;
(S)-N-[3-(3-Fluoro-4-[4-(4-methyl-1-oxo-1,2,3,4 tetrahydronaphthalen-2-yl methyl)-piperazin-1-yl]-phenyl)-2-oxo-oxazolidin-5-yl methyl]thioacetamide;
Trans-(S)-N-(3-{3-Fluoro-4-[4-(3-1H-pyrrol-2-yl-acryloyl)-piperazin-1-yl]- -phenyl}-2-oxo-oxazolidin-5-yl-methyl)acetamide; [[.]]
Cis-(S)-N-(3-{3-Fluoro-4-[4-(3-1H-pyrrol-2-yl-acryloyl)-piperazin-1-yl]-p- henyl}-2-oxo-oxazolidin-5-yl-methyl)acetamide; [[.]]

(S)-5-[3-(4-{4-[5-(Acetylamino-methyl)-2-oxo-oxazolin-3-yl]-2-fluoro-phen- yl}-piperazin-1-yl)-3-oxo-propenyl]-furan-2-carboxlic acid sodium salt (S)-5-[3-(4-{4-[5-(Acetylamino-methyl)-2-oxo-oxazolin-3-yl]-2-fluoro-phen- yl}-piperazin-1-yl)-3-oxo-propenyl]-furan-2-carboxlic acid; [[.]]

(S)-N-[3-(3-Fluoro-4-{4-[3-(5-hydroxymethyl-furan-2-yl)-acryloyl]-piperaz- in-1-yl}-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide; [[.]]

(S)-N-[3-(3-Fluoro-4-{4-[3-(4-methanesulfonyl-phenyl)-acryloyl]-piperazin- -1-yl}-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide; [[.]]

(S)-4-(4-{4-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl- }-piperazin-1-yl)-4-oxo-but-2-enoic acid; [[.]]

(S)-N-[3-(3-Fluoro-4-{4-[3-(5-formyl-furan-2-yl)-acryloyl]-piperazin-1-yl- }-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide; [[.]]

(S)-Acetic acid-5-[3-(4-{4-[5-(Acetylamino-methyl)-2-oxo-oxazolin-3-yl]-2-fluoro-phenyl}-piperazin-1-yl)-3-oxo-propenyl]-furan-2-yl methyl ester; [[.]]

(S)-4-(4-{4-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl- }-piperazin-1-yl)-4-oxo-but-2-enoic acid sodium salt; [[.]]

(S)-N-[3-(3-Fluoro-4-{4-[3-(5-methyl-furan-2-yl)-acryloyl]-piperazin-1-yl- }-phenyl)-2-oxo-oxazolidin-5-yl methyl]acetamide. (S)-N-[3-(3-Fluoro-4-{4-propynoyl-piperazin-1-yl]-phenyl)-2-oxo-oxazolidi- n-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-{4-(4-hydroxy-but-2-enoyl)-piperazin-1-yl]-phenyl)-2- -oxo-oxazolidin-5-yl methyl]acetamide;

(S)-N-[3-(3-Fluoro-4-{4-(4-bromo-but-2-enoyl)-piperazin-1-yl]-phenyl)-2-o- xo-oxazolidin-5-yl methyl]acetamide;

2-[4-(4-{5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl}-2-fluorophenyl)-pi- perazin-1-carbonyl]-3-phenyl-acrylic acid methyl ester;

2-[4-(4-{5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl}-2-fluorophenyl)-pi- perazin-1-carbonyl]-3-phenyl-acrylic acid;

2-[4-(4-{5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl}-2-fluorophenyl)-pi- perazin-1-carbonyl]-3-furane acrylic acid methyl ester; and

2-[4-(4-{5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl}-2-fluorophenyl)-pi- perazin-1-carbonyl]-3-furane-acrylic acid. [[;]]

12. (currently amended) A pharmaceutical composition, which comprises a compound as defined in claim 11, and a pharmaceutically acceptable carrier, diluents or excipients ~~or solvate~~.

13. (currently amended) A pharmaceutical composition as claimed in claim 12[[,]] in the form of a tablet, capsule, powder, granules, syrup, solution or suspension.

14. (currently amended) A method for treating bacterial infections caused by Gram positive bacteria or[[,]] psoriasis[[,]] ~~arthritis~~ in mammals comprising administering a therapeutically acceptable amount of compounds of claim 11[[,]] or a therapeutically acceptable salt ~~or prodrug~~ thereof.

15. (currently amended) The method as claimed in claim 14 wherein the compound or therapeutically acceptable salt thereof is administered orally, nasally, parenterally, topically, transdermally, or rectally.

16. (withdrawn/currently amended) A method for treating toxicity due to chemotherapy in a patient comprising administering a therapeutically acceptable amount of compounds of claim 11[[,]] or a therapeutically acceptable salt ~~or prodrug~~ thereof.

17. (withdrawn/currently amended) The method as claimed in claim 16 wherein the compound or therapeutically acceptable salt thereof is administered orally, nasally, parenterally, topically, transdermally, or rectally.

Claims 18-20 (canceled)

21. (currently amended) A process for the preparation of a compound of formula (I) as claimed in claim 1~~, where all symbols are as defined earlier, and including their derivatives, their analogs, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates,~~ which comprises any one of the following processes:

i) [[.]] by reacting a compound of formula (1a) with a compound of formula (1b)



(1a) (1b) (I)

where all symbols are as defined earlier and R represents OH, halide or an acyloxy group, to yield compound of formula (I) or [[.]]

ii) by reacting a compound of formula (1c) with a compound of formula (1b)



(1c) (1b) (I)

where all symbols are as defined earlier, to yield compounds of formula (I) or [[.]]

iii) by reacting ~~Reacting~~ a compound of formula (1m) with a compound of formula (1b) to give a compound of formula (1n)[[:]]



(1m) (1b) (1n)

where all symbols are as defined earlier; The compound (1n) represents compound of formula (I), where Y represents G_3 as defined in claim 1.

22. (currently amended) A process of converting compounds of formula (I) to further compounds of formula (I), which comprises any one of the following processes:

a) reacting of a compound of formula (1a) with a compound of formula (1d) to yield (1e), in the presence of (i) bases selected from Na_2CO_3, K_2CO_3, triethylamine, pyridine, diisopropylethylamine or their mixtures in solvents selected from acetone or THF when R does not represent OH or (ii) bases selected from DCC or HOBT in solvents selected from dichloromethane or chloroform when R represents OH or



(1a) (1d) (1e)

b) Converting a compound of formula (1e) to (1f) where L represents a leaving group such as --OMs, --OTs, halides etc. sulfonyl chlorides selected from p-Ts-chloride, MsCl, benzene sulfonyl chloride in presence of bases selected from triethylamine, pyridine, K_2CO_3 or mixture thereof, in solvents selected from DMF, DMSO, dichloromethane, dichloroethane, pyridine or their suitable mixtures



(1e) (1f)

alternatively, the compounds of general formula (1f), where L is halide, may be obtained by treating the compounds of general formula (Ie) with $SOCl_2$, $POCl_3$, PCl_5, PBr_3, HBr / red P, in the presence of solvents selected from DMF, DMSO, THF, benzene, CH_2Cl_2, dichloroethane or

c) Converting compound (1f) to (1g)

(1f) (1g)

d) Converting compound (1g) to (1h) triphenylphosphine and aqueous NH_3 or H_2O in alcoholic solvents or

(1g) (1h)

e) Converting (1h) to (1i) or



(1h) (1i)

f) Converting (1i) to (1j) by treating (1i) with ammonia in alcoholic solvents at temperatures ranging between -10°C to 50°C to obtain compounds of general formula (1j), where R_7 is NH_2



(1i) (1j)

Alternatively,

g) Converting compound (1i) to (1k) by treating (1i) with alkyl halides in solvents selected from ether or THF, at low temperature



(1i) (1k)

Alternatively

h) Converting compound (1i) to (1l) by treating (1i) with metal hybrids selected from sodium hybrids at low temperature in anhydrous alcohols as a solvent as well as a reactant



(1i) (1l)

where all symbols are as defined earlier and compounds of formula (Ie), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), represent compounds of formula (I), and W represents OH, N_3, NH_2, NCS, $NHCSR_7$, $NHCSSR_7$, $NHCSOR_7$ respectively, and Y represents G_2 with X=O.